English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data

Keil, M., Conrad, T., Becker, M., Keilholz, U., Yaspo, M.-L., Lehrach, H., et al. (2021). Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data. cancers, 13(23): 6018. doi:10.3390/cancers13236018.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files
hide Files
:
Keil et al_2021.pdf (Publisher version), 4MB
Name:
Keil et al_2021.pdf
Description:
This article belongs to the Special Issue Colorectal Cancers: From Present Problems to Future Solutions.
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
© 2021 by the authors

Locators

show

Creators

show
hide
 Creators:
Keil, Marlen , Author
Conrad, Theresia, Author
Becker, Michael , Author
Keilholz, Ulrich , Author
Yaspo, Marie-Laure1, Author              
Lehrach, Hans2, Author              
Schütte, Moritz , Author
Haybaeck, Johannes , Author
Hoffmann, Jens , Author
Affiliations:
1Gene Regulation and Systems Biology of Cancer (Marie-Laure Yaspo), Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_2117287              
2Emeritus Group of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_2385697              

Content

show
hide
Free keywords: colon cancer; personalized treatment; drug combinations
 Abstract: The current standard therapies for advanced, recurrent or metastatic colon cancer are the 5-fluorouracil and oxaliplatin or irinotecan schedules (FOxFI) +/− targeted drugs cetuximab or bevacizumab. Treatment with the FOxFI cytotoxic chemotherapy regimens causes significant toxicity and might induce secondary cancers. The overall low efficacy of the targeted drugs seen in colon cancer patients still is hindering the substitution of the chemotherapy. The ONCOTRACK project developed a strategy to identify predictive biomarkers based on a systems biology approach, using omics technologies to identify signatures for personalized treatment based on single drug response data. Here, we describe a follow-up project focusing on target-specific drug combinations. Back- ground for this experimental preclinical study was that, by analyzing the tumor growth inhibition in the PDX models by cetuximab treatment, a broad heterogenic response from complete regression to tumor growth stimulation was observed. To provide confirmation of the hypothesis that drug combinations blocking alternatively activated oncogenic pathways may improve therapy outcomes, 25 models out of the well-characterized ONCOTRACK PDX panel were subjected to treatment with a drug combination scheme using four approved, targeted cancer drugs.

Details

show
hide
Language(s): eng - English
 Dates: 2021-11-252021-11-30
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.3390/cancers13236018
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: cancers
Source Genre: Proceedings
 Creator(s):
Affiliations:
Publ. Info: Basel, Switzerland : Multidisciplinary Digital Publishing Institute (MDPI)
Pages: - Volume / Issue: 13 (23) Sequence Number: 6018 Start / End Page: - Identifier: ISSN: 2072-6694